Deciphering Mechanisms Underlying Cancer Immunogenicity — DECIDE  

Ovarian Cancer Clinical Trial

Official title: Deciphering Mechanisms Underlying Cancer Immunogenicity

Status Recruiting

Clinical Trial Summary

This trial is a translational, open-label, multicentric, prospective cohort study of 900 patients aiming to describe the PD-1 (programmed death) expression in T cells (T lymphocytes) in different solid tumors.

The study will be conducted on a population of patients with local and/or metastatic malignant solid tumor and who are followed within a standard of care procedure or clinical trial.

Patients with any of the following tumor types may be enrolled in the trial:

• Head and neck cancer,

• Ovarian cancer,

• Cervical cancer,

• Pre-invasive CIN III cervical cancer (Cervical Intra-epithelial Neoplasia III cervical cancer),

• Other solid tumor types (including glioblastoma, NSCLC (Non-small cell lung cancer), anal cancer)

Each tumor type will be considered as an independent cohort.

For each included patient, biological specimen (tumor sample, blood samples and ascites samples if applicable) will be collected.

Study participation of each patient will be 5 years.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Anal Cancer
• Anus Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Cervical Cancer
• Cervical Intraepithelial Neoplasia 3
• Glioblastoma
• Glioblastoma Multiforme of Brain Stem
• Head and Neck Cancer
• Head and Neck Neoplasms
• Neoplasms
• Non Small Cell Lung Cancer
• Ovarian Cancer
• Ovarian Neoplasms
• Uterine Cervical Dysplasia
• Uterine Cervical Neoplasms

• NCT number: NCT03958240
• Study type: Interventional
• Source: Institut Claudius Regaud
• Contact: Alejandra MARTINEZ
• Phone: +33 5 31 15 53 66
• Email: martinez.alejandra@iuct-oncopole.fr
• Status: Recruiting
• Phase: N/A
• Start date: January 17, 2020
• Completion date: September 2029